Technical Analysis for GH - Guardant Health, Inc.

Grade Last Price % Change Price Change
grade B 87.6 1.08% 0.94
GH closed up 1.8 percent on Wednesday, February 19, 2020, on 87 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Feb 24
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical GH trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 1.08%
Upper Bollinger Band Walk Strength 1.08%
Above Upper BB Strength 1.08%
Overbought Stochastic Strength 1.08%
Up 3 Days in a Row Strength 1.08%
Upper Bollinger Band Touch Strength 1.08%
Pocket Pivot Bullish Swing Setup 2.90%
Overbought Stochastic Strength 2.90%
Upper Bollinger Band Touch Strength 2.90%
180 Bullish Setup Bullish Swing Setup 3.91%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.
Medicine Biopharmaceutical Cancer Medical Specialties Disease Oncology Precision Medicine

Is GH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 112.21
52 Week Low 53.25
Average Volume 820,899
200-Day Moving Average 80.29
50-Day Moving Average 79.45
20-Day Moving Average 80.44
10-Day Moving Average 81.46
Average True Range 3.12
ADX 14.53
+DI 29.26
-DI 13.74
Chandelier Exit (Long, 3 ATRs ) 78.62
Chandelier Exit (Short, 3 ATRs ) 83.61
Upper Bollinger Band 86.23
Lower Bollinger Band 74.64
Percent B (%b) 1.04
BandWidth 14.42
MACD Line 1.32
MACD Signal Line 0.57
MACD Histogram 0.7549
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 90.32
Resistance 3 (R3) 90.35 89.16 89.71
Resistance 2 (R2) 89.16 88.23 89.15 89.51
Resistance 1 (R1) 87.91 87.65 88.54 87.88 89.30
Pivot Point 86.72 86.72 87.03 86.71 86.72
Support 1 (S1) 85.47 85.79 86.10 85.44 84.02
Support 2 (S2) 84.28 85.21 84.27 83.81
Support 3 (S3) 83.03 84.28 83.61
Support 4 (S4) 83.00